biote Corp - Class A risk profile
44 Elevated one input has moved against it
Measured 21 October 2026 from BTMD's filed statements. Recomputed nightly.
44 (Elevated), driven by Concentration at 100, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 83 | Acute | Volatile | One-year price volatility — 74.8% |
| Operating pressure | 17 | Contained | Easing | Costs outgrowing revenue — -2.9 percentage points |
| Cash conversion | 23 | Normal | Worsening | Cash conversion — 1.30x |
| Leverage and coverage | 44 | Elevated | Stable | Interest cover — 3.58x |
| Competitive position | 19 | Contained | Stable | Revenue-growth gap against peers — +6.1 percentage points |
| Concentration | 100 | Acute | Stable | Geographic concentration — 10,000 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for biote Corp - Class A